This is a truly strange one! Can't see why they would convene said meeting ahead of trial completion unless there was an interest in an early approval, or at least a lot of pressure to identify treatments that might reduce opioid use. Maybe preparation for approval at the interim analysis. Looking forward to finding out more about that at the AGM.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation
MSB
mesoblast limited
Add to My Watchlist
2.44%
!
$2.10
Ann: FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation, page-5
-
Top Stories
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.